Real	O
-	O
time	O
analysis	O
of	O
gut	B-OG
flora	I-OG
in	O
Entamoeba	B-OG
histolytica	I-OG
infected	O
patients	O
of	O
Northern	O
India	O

Background	O

Amebic	B-DS
dysentery	I-DS
is	O
caused	O
by	O
the	O
protozoan	O
parasite	O
Entamoeba	B-OG
histolytica	I-OG
and	O
the	O
ingestion	O
of	O
quadrinucleate	O
cyst	O
of	O
E	B-OG
.	I-OG
histolytica	I-OG
from	O
fecally	O
contaminated	O
food	O
or	O
water	O
initiates	O
infection	B-DS
.	O

Excystation	O
occurs	O
in	O
the	O
lumen	O
of	O
small	O
intestine	O
,	O
where	O
motile	O
and	O
potentially	O
invasive	O
trophozoites	O
germinate	O
from	O
cysts	O
.	O

The	O
ability	O
of	O
trophozoites	O
to	O
interact	O
and	O
digest	O
gut	O
bacteria	B-OG
is	O
apparently	O
important	O
for	O
multiplication	O
of	O
the	O
parasite	O
and	O
its	O
pathogenicity	O
;	O
however	O
the	O
contribution	O
of	O
resident	O
bacterial	O
flora	O
is	O
not	O
well	O
understood	O
.	O

We	O
quantified	O
the	O
population	O
of	O
Bacteroides	B-OG
,	O
Bifidobacterium	B-OG
,	O
Ruminococcus	B-OG
,	O
Lactobacillus	B-OG
,	O
Clostridium	B-OG
leptum	I-OG
subgroup	O
,	O
Clostridium	B-OG
coccoides	I-OG
subgroup	O
,	O
Eubacterium	B-OG
,	O
Campylobacter	B-OG
,	O
Methanobrevibacter	B-OG
smithii	I-OG
and	O
Sulphur	B-OG
reducing	I-OG
bacteria	I-OG
using	O
genus	O
specific	O
primers	O
in	O
healthy	O
(	O
N	O
=	O
22	O
)	O
vs	O
amebic	O
patients	O
(	O
E	B-OG
.	I-OG
histolytica	I-OG
positive	O
,	O
N	O
=	O
17	O
)	O
stool	O
samples	O
by	O
Real	O
-	O
time	O
PCR	O
.	O

Results	O

Absolute	O
quantification	O
of	O
Bacteroides	B-OG
(	O
p	O
=	O
.	O
001	O
),	O
Closrtridium	B-OG
coccoides	I-OG
subgroup	O
(	O
p	O
=	O
0	O
.	O
002	O
),	O
Clostridium	B-OG
leptum	I-OG
subgroup	O
(	O
p	O
=	O
0	O
.	O
0001	O
),	O
Lactobacillus	B-OG
(	O
p	O
=	O
0	O
.	O
037	O
),	O
Campylobacter	B-OG
(	O
p	O
=	O
0	O
.	O
0014	O
)	O
and	O
Eubacterium	B-OG
(	O
p	O
=	O
0	O
.	O
038	O
)	O
show	O
significant	O
drop	O
in	O
their	O
population	O
however	O
,	O
significant	O
increase	O
in	O
Bifdobacterium	B-OG
(	O
p	O
=	O
0	O
.	O
009	O
)	O
was	O
observed	O
where	O
as	O
the	O
population	O
of	O
Ruminococcus	B-OG
(	O
p	O
=	O
0	O
.	O
33	O
)	O
remained	O
unaltered	O
in	O
healthy	O
vs	O
amebic	O
patients	O
(	O
E	B-OG
.	I-OG
histolytica	I-OG
positive	O
).	O

We	O
also	O
report	O
high	O
prevalence	O
of	O
nimE	B-GP
gene	O
in	O
stool	O
samples	O
of	O
both	O
healthy	O
volunteers	O
and	O
amebic	O
patients	O
.	O

No	O
significant	O
decrease	O
in	O
nimE	B-GP
gene	O
copy	O
number	O
was	O
observed	O
before	O
and	O
after	O
the	O
treatment	O
with	O
antiamebic	O
drug	O
.	O

Conclusions	O

Our	O
results	O
show	O
significant	O
alteration	O
in	O
predominant	O
gut	O
bacteria	B-OG
in	O
E	B-OG
.	I-OG
histolytica	I-OG
infected	O
individuals	O
.	O

The	O
frequent	O
episodes	O
of	O
intestinal	O
amoebic	B-DS
dysentery	I-DS
thus	O
result	O
in	O
depletion	O
of	O
few	O
predominant	O
genera	O
in	O
gut	O
that	O
may	O
lead	O
to	O
poor	O
digestion	O
and	O
absorption	O
of	O
food	O
in	O
intestine	O
.	O

It	O
further	O
disturbs	O
the	O
homeostasis	O
between	O
gut	O
epithelium	O
and	O
bacterial	O
flora	O
.	O

The	O
decrease	O
in	O
beneficial	O
bacterial	O
population	O
gives	O
way	O
to	O
dysbiosis	O
of	O
gut	O
bacteria	B-OG
which	O
may	O
contribute	O
to	O
final	O
outcome	O
of	O
the	O
disease	O
.	O

Increase	O
in	O
the	O
copy	O
number	O
of	O
nimE	B-GP
gene	O
harboring	O
bacteria	B-OG
in	O
our	O
population	O
reflects	O
possible	O
decrease	O
in	O
the	O
availability	O
of	O
metronidazole	O
drug	O
during	O
treatment	O
of	O
amoebiasis	B-DS
.	O

Background	O

Entamoeba	B-OG
histolytica	I-OG
,	O
a	O
micro	O
-	O
aerophilic	O
intestinal	O
protozoan	O
parasite	O
and	O
the	O
causative	O
agent	O
of	O
invasive	O
amoebiasis	B-DS
(	O
colitis	B-DS
and	O
amoebic	B-DS
liver	I-DS
abscess	I-DS
),	O
remains	O
a	O
significant	O
cause	O
of	O
morbidity	O
and	O
mortality	O
in	O
developing	O
countries	O
[	O
1	O
].	O

It	O
is	O
well	O
known	O
that	O
the	O
parasite	O
is	O
constantly	O
interacting	O
with	O
the	O
intestinal	O
gut	B-OG
flora	I-OG
however	O
the	O
contribution	O
of	O
the	O
flora	O
in	O
the	O
manifestation	O
of	O
the	O
disease	O
is	O
poorly	O
understood	O
.	O

The	O
human	B-OG
gastrointestinal	O
(	O
GI	O
)	O
tract	O
is	O
nutrient	O
-	O
rich	O
environment	O
packed	O
with	O
a	O
complex	O
and	O
dynamic	O
consortia	O
of	O
trillions	O
of	O
microbes	B-OG
[	O
2	O
].	O
The	O
vast	O
majority	O
reside	O
in	O
our	O
colon	O
where	O
densities	O
approach	O
1011	O
-	O
1012	O
cells	O
/	O
ml	O
,	O
the	O
highest	O
density	O
recorded	O
for	O
any	O
microbial	O
habitat	O
[	O
3	O
].	O

About	O
500	O
–	O
1000	O
bacterial	O
species	O
colonize	O
the	O
adult	O
intestine	O
,	O
with	O
30	O
–	O
40	O
species	O
comprising	O
up	O
to	O
97	O
%	O
of	O
the	O
total	O
population	O
[	O
4	O
,	O
5	O
].	O
Bacteroides	B-OG
,	O
Bifidobacterium	B-OG
,	O
Eubacterium	B-OG
,	O
Clostridium	B-OG
,	O
Peptococcus	B-OG
,	O
Peptostreptococcus	B-OG
,	O
Lactobacillus	B-OG
and	O
Ruminococcus	B-OG
are	O
considered	O
to	O
be	O
predominant	O
genera	O
whereas	O
Enterococcus	B-OG
,	O
Methanobrevibacter	B-OG
and	O
sulphur	B-OG
reducing	I-OG
bacteria	I-OG
(	O
SRB	B-OG
)	O
remain	O
as	O
the	O
subdominant	O
genera	O
[	O
6	O
].	O

The	O
entire	O
system	O
of	O
the	O
human	B-OG
gut	O
microbiota	B-OG
functions	O
as	O
a	O
‘	O
microbial	O
organ	O
’	O
within	O
the	O
intestine	O
,	O
which	O
contributes	O
to	O
diverse	O
mammalian	O
processes	O
including	O
protective	O
functions	O
against	O
pathogens	O
and	O
immune	O
-	O
system	O
modulation	O
,	O
the	O
metabolic	O
function	O
of	O
fermenting	O
non	O
-	O
digestible	O
dietary	O
fiber	O
,	O
anaerobic	O
metabolism	O
of	O
peptides	O
and	O
proteins	O
that	O
results	O
in	O
the	O
recovery	O
of	O
metabolic	O
energy	O
for	O
the	O
host	O
[	O
7	O
].	O

The	O
microbial	O
diversity	O
of	O
the	O
human	B-OG
gut	O
is	O
the	O
result	O
of	O
co	O
-	O
evolution	O
between	O
microbial	O
communities	O
and	O
their	O
hosts	O
.	O

Microbial	O
community	O
structure	O
is	O
a	O
very	O
important	O
factor	O
that	O
can	O
influence	O
predisposition	O
to	O
specific	O
diseases	O
in	O
certain	O
host	O
contexts	O
[	O
8	O
].	O

Ingestion	O
of	O
the	O
cyst	O
of	O
E	B-OG
.	I-OG
histolytica	I-OG
through	O
fecally	O
contaminated	O
food	O
or	O
water	O
initiates	O
infection	B-DS
.	O

Excystation	O
in	O
the	O
intestinal	O
lumen	O
produces	O
trophozoites	O
and	O
colitis	B-DS
results	O
when	O
the	O
trophozoites	O
penetrate	O
the	O
mucus	O
layer	O
and	O
damages	O
intestinal	O
tissues	O
[	O
9	O
].	O

The	O
trophozoites	O
proliferate	O
in	O
lumen	O
and	O
phagocytose	O
resident	O
flora	O
.	O
E	B-OG
.	I-OG
histolytica	I-OG
trophozoites	O
are	O
quite	O
selective	O
in	O
respect	O
to	O
their	O
interactions	O
with	O
different	O
bacterial	O
species	O
and	O
only	O
those	O
bacteria	B-OG
which	O
have	O
the	O
appropriate	O
recognition	O
molecules	O
get	O
attached	O
and	O
ingested	O
[	O
10	O
].	O

It	O
has	O
been	O
observed	O
that	O
the	O
nuclear	O
DNA	O
content	O
of	O
E	B-OG
.	I-OG
histolytica	I-OG
trophozoites	O
growing	O
in	O
axenic	O
cultures	O
is	O
at	O
least	O
10	O
fold	O
higher	O
than	O
in	O
xenic	O
cultures	O
and	O
re	O
-	O
association	O
of	O
axenic	O
cultures	O
with	O
their	O
bacterial	O
flora	O
led	O
to	O
a	O
reduction	O
of	O
DNA	O
content	O
attaining	O
the	O
original	O
xenic	O
values	O
indicating	O
a	O
flexible	O
nature	O
of	O
the	O
parasite	O
genome	O
[	O
11	O
].	O

Fluctuations	O
in	O
gut	B-OG
flora	I-OG
have	O
been	O
reported	O
both	O
in	O
acute	B-DS
diarrhea	I-DS
and	O
antibiotic	B-DS
associated	I-DS
diarrhea	I-DS
[	O
12	O
],	O
but	O
very	O
few	O
reports	O
are	O
available	O
on	O
status	O
of	O
gut	B-OG
flora	I-OG
in	O
E	B-OG
.	I-OG
histolytica	I-OG
infected	O
individuals	O
.	O

Earlier	O
studies	O
in	O
our	O
laboratory	O
[	O
1	O
]	O
have	O
recorded	O
fluctuations	O
in	O
the	O
gut	B-OG
flora	I-OG
by	O
a	O
qualitative	O
method	O
during	O
disease	O
conditions	O
.	O

5	O
-	O
Nitroimidazole	O
drugs	O
are	O
still	O
used	O
as	O
first	O
line	O
of	O
defense	O
against	O
amoebic	O
and	O
other	O
infections	B-DS
caused	O
by	O
anaerobes	O
.	O

These	O
drugs	O
are	O
administered	O
as	O
pro	O
drugs	O
and	O
one	O
electron	O
reduction	O
of	O
nitro	O
group	O
converts	O
the	O
pro	O
drug	O
into	O
an	O
active	O
drug	O
[	O
13	O
].	O

Enzymatic	O
modification	O
mediated	O
by	O
nim	B-GP
-	O
class	O
of	O
genes	O
is	O
a	O
well	O
characterized	O
resistance	O
mechanism	O
.	O

Certain	O
Bacteroides	B-OG
species	O
which	O
are	O
members	O
of	O
the	O
normal	O
colonic	O
human	B-OG
microflora	B-OG
harbor	O
nim	B-GP
genes	O
[	O
14	O
].	O

Our	O
study	O
is	O
based	O
on	O
the	O
hypothesis	O
that	O
the	O
Entamoeba	B-OG
histolytica	I-OG
(	O
but	O
not	O
E	B-OG
.	I-OG
dispar	I-OG
)	O
is	O
an	O
invasive	O
organism	O
and	O
invades	O
the	O
mucus	O
layer	O
and	O
subsequently	O
the	O
intestinal	O
epithelium	O
for	O
colonization	O
using	O
the	O
pathogenic	O
factors	O
.	O

In	O
this	O
context	O
we	O
attempted	O
to	O
study	O
the	O
fluctuations	O
in	O
the	O
gut	O
microbiota	B-OG
that	O
contributes	O
to	O
substantial	O
metabolic	O
changes	O
in	O
E	B-OG
.	I-OG
histolytica	I-OG
infected	O
individuals	O
compared	O
to	O
healthy	O
individuals	O
.	O

In	O
the	O
present	O
study	O
we	O
used	O
Real	O
Time	O
PCR	O
for	O
absolute	O
quantification	O
of	O
predominant	O
gut	O
bacterial	O
population	O
in	O
E	B-OG
.	I-OG
histolytica	I-OG
patients	O
suffering	O
from	O
dysentery	B-DS
for	O
5	O
–	O
7	O
days	O
.	O

We	O
also	O
quantified	O
the	O
copy	O
number	O
of	O
nim	B-GP
gene	O
in	O
stool	O
sample	O
of	O
healthy	O
vs	O
E	B-OG
.	I-OG
histolytica	I-OG
patients	O
.	O

Methods	O

Study	O
subjects	O
&	O
fecal	O
sample	O
collection	O

Stool	O
samples	O
of	O
healthy	O
person	O
(	O
without	O
any	O
enteric	O
disease	O
)	O
were	O
collected	O
as	O
controls	O
from	O
volunteers	O
of	O
a	O
community	O
in	O
Delhi	O
.	O

Initial	O
survey	O
involved	O
discussion	O
with	O
the	O
focus	O
group	O
and	O
informed	O
consent	O
was	O
taken	O
from	O
participating	O
volunteers	O
for	O
the	O
study	O
.	O

Volunteers	O
in	O
age	O
group	O
of	O
21	O
–	O
40	O
year	O
(	O
mean	O
age	O
31	O
year	O
)	O
were	O
randomly	O
recruited	O
.	O

Subjects	O
who	O
have	O
taken	O
any	O
antibiotic	O
/	O
antiamoebic	O
drug	O
or	O
suffered	O
from	O
any	O
gastrointestinal	B-DS
disorder	I-DS
in	O
past	O
one	O
month	O
before	O
sample	O
collection	O
were	O
not	O
included	O
in	O
the	O
study	O
.	O

Twenty	O
two	O
stool	O
samples	O
were	O
collected	O
from	O
healthy	O
volunteers	O
.	O

Clinical	O
diagnosis	O
of	O
amoebic	B-DS
colitis	I-DS
was	O
based	O
on	O
standard	O
criteria	O
:	O
patients	O
experiencing	O
days	O
to	O
weeks	O
of	O
dysentery	B-DS
(	O
stool	O
with	O
blood	O
and	O
mucus	O
)	O
or	O
diarrhea	O
with	O
cramps	O
followed	O
by	O
abdominal	O
pain	O
and	O
/	O
or	O
weight	O
loss	O
.	O

The	O
sub	O
acute	O
onset	O
of	O
the	O
disease	O
was	O
a	O
helpful	O
clue	O
in	O
the	O
differential	O
diagnosis	O
because	O
bacillary	B-DS
dysentery	I-DS
caused	O
by	O
Shigella	B-OG
,	O
Salmonella	B-OG
,	O
Campylobacter	B-OG
and	O
EHEC	B-OG
E	I-OG
.	I-OG
coli	I-OG
mostly	O
lead	O
to	O
a	O
abrupt	O
onset	O
of	O
the	O
disease	O
[	O
15	O
].	O

Since	O
we	O
did	O
not	O
take	O
samples	O
from	O
individuals	O
administered	O
with	O
any	O
antibiotic	O
,	O
therefore	O
cases	O
of	O
antibiotic	B-DS
associated	I-DS
diarrhea	I-DS
were	O
excluded	O
.	O

Stool	O
samples	O
of	O
chronic	O
/	O
acute	B-DS
diarrhea	I-DS
as	O
diagnosed	O
by	O
Gastroenterologist	O
were	O
collected	O
from	O
Gastroenterology	O
department	O
of	O
All	O
India	O
Institute	O
of	O
Medical	O
Sciences	O
&	O
Safdarjung	O
hospitals	O
,	O
New	O
Delhi	O
.	O

The	O
samples	O
were	O
transported	O
to	O
the	O
laboratory	O
at	O
4	O
°	O
C	O
within	O
2	O
hrs	O
and	O
stored	O
at	O
-	O
20	O
°	O
C	O
until	O
processed	O
.	O

The	O
study	O
was	O
approved	O
by	O
the	O
research	O
ethics	O
board	O
of	O
respective	O
institutes	O
.	O

The	O
samples	O
(	O
n	O
=	O
550	O
)	O
were	O
collected	O
with	O
the	O
informed	O
consent	O
of	O
the	O
patients	O
.	O

Enrichment	O
of	O
entamoeba	B-OG
cysts	O

Cysts	O
were	O
enriched	O
following	O
the	O
protocol	O
of	O
Knight	O
et	O
al	O
.,	O
1976	O
[	O
16	O
]	O
with	O
slight	O
modifications	O
.	O

Briefly	O
,	O
fecal	O
samples	O
(	O
1gm	O
)	O
were	O
homogenized	O
in	O
10	O
ml	O
of	O
autoclaved	O
distilled	O
water	O
,	O
strained	O
through	O
cheesecloth	O
in	O
50	O
ml	O
falcon	O
tube	O
.	O

This	O
suspension	O
was	O
centrifuged	O
at	O
2000	O
rpm	O
for	O
5	O
min	O
and	O
pellet	O
was	O
re	O
-	O
dissolved	O
in	O
10	O
ml	O
of	O
10	O
%	O
formaldehyde	O
.	O

3	O
ml	O
of	O
diethyl	O
ether	O
was	O
added	O
to	O
the	O
tube	O
and	O
this	O
mixture	O
was	O
vortexed	O
and	O
incubated	O
at	O
RT	O
for	O
30	O
min	O
.	O

The	O
mixture	O
was	O
subjected	O
to	O
centrifugation	O
at	O
2000	O
rpm	O
for	O
5	O
min	O
,	O
supernatant	O
was	O
removed	O
and	O
pellet	O
was	O
washed	O
with	O
double	O
distilled	O
water	O
.	O

The	O
Pellet	O
containing	O
concentrated	O
cyst	O
was	O
re	O
-	O
dissolved	O
in	O
400	O
μl	O
T10E1	O
buffer	O
.	O

Cysts	O
in	O
T10E1	O
buffer	O
was	O
subjected	O
to	O
freeze	O
-	O
thaw	O
cycle	O
and	O
thereafter	O
to	O
sonication	O
in	O
order	O
to	O
obtain	O
crude	O
DNA	O
for	O
Dot	O
-	O
blot	O
hybridization	O
experiment	O
.	O

Screening	O
of	O
samples	O
by	O
dot	O
blot	O
hybridization	O

The	O
crude	O
cyst	O
DNA	O
was	O
denatured	O
by	O
addition	O
of	O
NaOH	O
to	O
final	O
concentration	O
of	O
0	O
.	O
25	O
N	O
in	O
a	O
total	O
volume	O
of	O
300	O
μl	O
.	O

The	O
DNA	O
was	O
kept	O
at	O
room	O
temperature	O
for	O
30	O
minutes	O
and	O
then	O
transferred	O
on	O
to	O
ice	O
.	O

The	O
GS	O
+	O
nylon	O
membrane	O
of	O
required	O
size	O
was	O
cut	O
and	O
saturated	O
in	O
0	O
.	O
4	O
M	O
Tris	O
-	O
Cl	O
,	O
pH	O
7	O
.	O
5	O
for	O
15	O
min	O
and	O
the	O
DNA	O
were	O
spotted	O
on	O
to	O
the	O
membrane	O
with	O
the	O
help	O
of	O
mini	O
-	O
fold	O
apparatus	O
from	O
Whatman	O
,	O
Germany	O
.	O

The	O
blots	O
were	O
air	O
dried	O
and	O
UV	O
cross	O
linked	O
before	O
hybridization	O
.	O

We	O
used	O
4	O
.	O
5	O
kb	O
rDNA	O
fragment	O
(	O
EcoRI	B-GP
to	O
Hind	B-GP
III	I-GP
site	O
)	O
from	O
HMe	O
region	O
of	O
EhR1	O
(	O
rDNA	O
plasmid	O
in	O
HM1	O
:	O
IMSS	O
strain	O
of	O
E	B-OG
.	I-OG
histolytica	I-OG
)	O
as	O
probe	O
for	O
detection	O
of	O
Entamoeba	B-OG
positive	O
samples	O
that	O
include	O
both	O
E	B-OG
.	I-OG
histolytica	I-OG
and	O
E	B-OG
.	I-OG
dispar	I-OG
(	O
Figure	O
1A	O
)	O
[	O
17	O
].	O

Screening	O
of	O
stool	O
samples	O
by	O
Dot	O
-	O
Blot	O
method	O
.	O
(	O
A	O
)	O
Linear	O
map	O
of	O
EhRI	O
episome	O
(	O
24	O
.	O
5	O
kb	O
)	O
showing	O
the	O
position	O
of	O
HMe	O
probe	O
(	O
4	O
.	O
5	O
kb	O
in	O
size	O
)	O
common	O
for	O
both	O
E	B-OG
.	I-OG
histolytica	I-OG
and	O
E	B-OG
.	I-OG
dispar	I-OG
),	O
E	O
-	O
EcoR1	B-GP
site	O
and	O
H	O
-	O
Hind	B-GP
III	I-GP
site	O
;	O
rDNA	O
I	O
and	O
rDNA	O
II	O
represent	O
two	O
inverted	O
repeats	O
of	O
transcription	O
units	O
with	O
various	O
restriction	O
sites	O
and	O
repeats	O
(	O
B	O
)	O
Representative	O
figure	O
of	O
Dot	O
-	O
blot	O
analysis	O
of	O
stool	O
sample	O
using	O
HMe	O
probe	O
.	O

Rows	O
1	O
to	O
6	O
(	O
column	O
A	O
-	O
D	O
)	O
represent	O
spots	O
of	O
DNA	O
from	O
stool	O
samples	O
.	O

About	O
20	O
ng	O
of	O
DNA	O
was	O
loaded	O
on	O
each	O
spot	O
in	O
triplicate	O
on	O
nylon	O
membrane	O
.	O

Row	O
7	O
was	O
blank	O
.	O

Row	O
8	O
(	O
column	O
A	O
)	O
E	B-OG
.	I-OG
histolytica	I-OG
HM1	I-OG
:	I-OG
IMSS	I-OG
genomic	O
DNA	O
as	O
positive	O
control	O
;	O
(	O
column	O
B	O
)	O
E	B-OG
.	I-OG
dispar	I-OG
SAW760	I-OG
genomic	O
DNA	O
as	O
positive	O
control	O
;	O
(	O
column	O
C	O
)	O
E	B-OG
.	I-OG
Coli	I-OG
DH5α	I-OG
as	O
negative	O
control	O
;	O
(	O
column	O
D	O
)	O
Plasmid	O
with	O
cloned	O
HMe	O
as	O
positive	O
control	O
.	O

All	O
samples	O
were	O
loaded	O
in	O
triplicate	O
.	O

Experimental	O
details	O
are	O
provided	O
in	O
material	O
and	O
methods	O
.	O

Genomic	O
DNA	O
extraction	O

DNA	O
was	O
extracted	O
from	O
the	O
Dot	O
blot	O
positive	O
samples	O
.	O

An	O
aliquot	O
of	O
200	O
mg	O
stool	O
sample	O
was	O
used	O
for	O
isolation	O
using	O
QIAamp	O
mini	O
stool	O
kit	O
(	O
QIAGEN	O
,	O
Germany	O
)	O
as	O
per	O
manufacturer	O
’	O
s	O
guidelines	O
.	O

While	O
isolating	O
DNA	O
from	O
the	O
stool	O
samples	O
through	O
the	O
above	O
kit	O
,	O
pGEMT	O
-	O
easy	O
plasmid	O
containg	O
240	O
bp	O
fragment	O
of	O
glycoprotein	B-GP
B	I-GP
(	O
gB	B-GP
)	O
gene	O
of	O
phocine	B-OG
virus	I-OG
(	O
20	O
ng	O
/	O
200	O
μl	O
of	O
ASL	O
buffer	O
)	O
was	O
added	O
in	O
ASL	O
buffer	O
as	O
internal	O
control	O
during	O
the	O
isolation	O
of	O
genomic	O
DNA	O
[	O
18	O
].	O

PCR	O
analysis	O
of	O
Dot	O
blot	O
positive	O
samples	O

To	O
differentiate	O
Dot	O
-	O
blot	O
positive	O
samples	O
into	O
E	B-OG
.	I-OG
histolytica	I-OG
and	O
E	B-OG
.	I-OG
dispar	I-OG
,	O
primers	O
were	O
designed	O
from	O
EhSINE2	O
for	O
E	B-OG
.	I-OG
histolytica	I-OG
and	O
from	O
18	O
S	O
and	O
ITS2	O
region	O
of	O
rDNA	O
circle	O
for	O
E	B-OG
.	I-OG
dispar	I-OG
respectively	O
(	O
Figure	O
2A	O
&	O
B	O
).	O
Primer	O
sequences	O
were	O
as	O
follows	O
;	O
Eh	O
-	O
F	O
5	O
’-	O
GTCAGAGACACCACATGAA	O
-	O
3	O
’,	O
Eh	O
-	O
R	O
5	O
’-	O
GAGACCCCTTAAAGAAAC	O
-	O
CC	O
-	O
3	O
’	O
and	O
Ed	O
-	O
F	O
5	O
’-	O
GAAGAAACATTGTTTCTAAATCCAA	O
-	O
3	O
’	O
&	O
Ed	O
-	O
R	O
5	O
’-	O
TTTATTAA	O
CTC	O
ACTTATA	O
-	O
3	O
’	O
[	O
19	O
].	O

Screening	O
of	O
Stool	O
samples	O
by	O
PCR	O
.	O
(	O
A	O
)	O
Schematic	O
representation	O
of	O
location	O
of	O
Entamoeba	B-OG
histolytica	I-OG
specific	O
primer	O
.	O

BH16197	O
is	O
Genbank	O
accession	O
number	O
of	O
Entamoeba	B-OG
histolytica	I-OG
SINE	O
-	O
2	O
(	O
EhSINE2	O
)	O
element	O
;	O
(	O
B	O
)	O
Schematic	O
representation	O
of	O
location	O
of	O
Entamoeba	B-OG
dispar	I-OG
specific	O
primer	O
from	O
rDNA	O
molecule	O
.	O

18	O
S	O
,	O
5	O
.	O
8	O
S	O
and	O
28	O
S	O
are	O
corresponding	O
ribosomal	O
gene	O
sequences	O
and	O
ITS	O
-	O
1	O
and	O
ITS	O
-	O
2	O
refers	O
to	O
internal	O
transcribed	O
spacer	O
1	O
and	O
2	O
;	O
(	O
C	O
)	O
Detection	O
of	O
E	B-OG
.	I-OG
histolytica	I-OG
in	O
stool	O
DNA	O
sample	O
using	O
E	B-OG
.	I-OG
histolytica	I-OG
specific	O
primers	O
,	O
Lane	O
1	O
=	O
Marker	O
100	O
bp	O
,	O
Lane	O
2	O
=	O
EhHM1	O
genomic	O
DNA	O
as	O
positive	O
control	O
,	O
Lane	O
3	O
&	O
4	O
stool	O
sample	O
DNA	O
,	O
Lane	O
5	O
=	O
Genomic	O
DNA	O
of	O
E	B-OG
.	I-OG
dispar	I-OG
SAW760	I-OG
as	O
negative	O
control	O
.	O
Sample	O
in	O
lane	O
4	O
is	O
E	B-OG
.	I-OG
histolytica	I-OG
positive	O
;	O
(	O
D	O
)	O
Detection	O
of	O
E	B-OG
.	I-OG
dispar	I-OG
in	O
Stool	O
sample	O
using	O
E	B-OG
.	I-OG
dispar	I-OG
specific	O
primers	O
.	O

Lane	O
1	O
=	O
Marker	O
1	O
kb	O
,	O
Lane	O
2	O
,	O
3	O
,	O
4	O
and	O
5	O
stool	O
sample	O
DNA	O
,	O
Lane	O
6	O
=	O
Genomic	O
DNA	O
of	O
E	B-OG
.	I-OG
dispar	I-OG
as	O
positive	O
control	O
.	O

Sample	O
in	O
Lane	O
3	O
and	O
5	O
are	O
E	B-OG
.	I-OG
dispar	I-OG
positive	O
.	O

Lane	O
4	O
stool	O
sample	O
is	O
E	B-OG
.	I-OG
histolytica	I-OG
positive	O
and	O
was	O
used	O
as	O
negative	O
control	O
.	O

Primer	O
designing	O
for	O
detection	O
of	O
predominant	O
genera	O
of	O
gut	B-OG
flora	I-OG

Primer	O
sets	O
were	O
designed	O
to	O
differentiate	O
and	O
quantitate	O
the	O
following	O
major	O
anaerobic	O
genera	O
–	O
Bacteroides	B-OG
,	O
Clostridium	B-OG
,	O
Campylobacter	B-OG
,	O
Bifidobacterium	B-OG
,	O
Ruminococcus	B-OG
,	O
Eubacterium	B-OG
,	O
Lactobacillus	B-OG
,	O
Methanobrevibacter	B-OG
and	O
Sulfate	B-OG
-	I-OG
reducing	I-OG
bacteria	I-OG
(	O
SRB	B-OG
).	O
16S	O
rRNA	O
gene	O
was	O
targeted	O
for	O
designing	O
primers	O
except	O
for	O
SRB	B-OG
(	O
Table	O
1	O
).	O

Sulphate	O
reducing	O
gene	O
was	O
targeted	O
for	O
quantifying	O
members	O
of	O
SRB	B-OG
.	O

Primers	O
were	O
commercially	O
obtained	O
from	O
Sigma	O
-	O
aldrich	O
,	O
USA	O
.	O

Genus	O
specific	O
16S	O
rRNA	O
targeted	O
bacterial	O
primers	O
used	O
in	O
this	O
study	O

Sr	O
no	O
.	O

Genus	O

Primer	O
sequence	O

PCR	O
Product	O
(	O
bp	O
)	O

Tm	O
(	O
ºC	O
)	O

References	O

1	O
.	O

Methanobrevibactr	B-OG

F	O
5	O
’-	O
CGATGCGGACTTGGTGTTG	O
-	O
3	O
’	O

184	O

59	O
.	O
7	O

[	O
21	O
]	O

R	O
5	O
’-	O
TGTCGCCTCTGGTGAGATGTC	O
-	O
3	O
’	O


59	O
.	O
8	O


2	O
.	O

Peptostreptococcus	B-OG

F	O
5	O
’-	O
AACTCCGGTGGTATCAGATG	O
-	O
3	O
’	O

270	O

55	O
.	O
4	O

[	O
1	O
]	O

R	O
5	O
’-	O
GGGGCTTCTGAGTCAGGTA	O
-	O
3	O
’	O


56	O
.	O
4	O


3	O
.	O

Ruminococcus	B-OG

F	O
5	O
’-	O
GAAAGCGTGGGGAGCAAACAGG	O
-	O
3	O
’	O

302	O

65	O
.	O
8	O

[	O
21	O
]	O

R	O
5	O
’-	O
GACGACAACCATGCACCACCTG	O
-	O
3	O
’	O


64	O
.	O
4	O


4	O
.	O

Eubacterium	B-OG

F	O
5	O
’-	O
GTAGTCCACGCCGTAAACGATG	O
-	O
3	O
’	O

278	O

60	O
.	O
4	O

[	O
21	O
]	O

R	O
5	O
’-	O
ACACGAGCTGACGACAACCATG	O
-	O
3	O
’	O


62	O
.	O
4	O


5	O
.	O

Bacteroides	B-OG

F	O
5	O
’-	O
GGGGTTCTGAGAGGAAG	O
-	O
3	O
’	O

115	O

54	O
.	O
0	O

[	O
21	O
]	O

R	O
5	O
’-	O
GCTACTTGGCTGGTTCAG	O
-	O
3	O
’	O


56	O
.	O
0	O


6	O
.	O

Lactobacillus	B-OG

F	O
5	O
’-	O
GCAGCAGTAGGGAATCTTCCA	O
-	O
3	O
’	O

340	O

64	O
.	O
0	O

[	O
25	O
]	O

R	O
5	O
’-	O
GCATTYCACCGCTACACATG	O
-	O
3	O
’	O


58	O
.	O
0	O


7	O
.	O

Clostridium	B-OG
leptum	I-OG
subgroup	O

F	O
5	O
’-	O
CGTCAGCTCGTGTCGTGAGAT	O
-	O
3	O
’	O

125	O

60	O
.	O
0	O

[	O
21	O
]	O

R	O
5	O
’-	O
CGTCATCCCCACCTTCCTCC	O
-	O
3	O
’	O


62	O
.	O
5	O


8	O
.	O

Clostridium	B-OG
coccoides	I-OG
subgroup	O

F	O
5	O
’-	O
GCCACATTGGGACTGAGA	O
-	O
3	O
’	O

170	O

56	O
.	O
0	O

This	O
study	O

R	O
5	O
’-	O
GCTTCTTAGTCAGGTACCG	O
-	O
3	O
’	O


58	O
.	O
0	O


9	O
.	O

Campylobacter	B-OG

F	O
5	O
’-	O
AGGGAATATTGCGCAATGGGGGAAA	O
-	O
3	O
’	O

180	O

58	O
.	O
0	O

[	O
21	O
]	O

R	O
5	O
’-	O
GATTCCGAGTAACGCTTGCACCCT	O
-	O
3	O
’	O


59	O
.	O
0	O


10	O
.	O

Bifidobacterium	B-OG

F	O
5	O
’-	O
GATTCTGGCTCAGGATGAACGC	O
-	O
3	O
’	O

231	O

61	O
.	O
9	O

[	O
21	O
]	O

R	O
5	O
’-	O
CTGATAGGACGCGACCCCAT	O
-	O
3	O
’	O


60	O
.	O
8	O


11	O
.	O

Sulfate	B-OG
-	I-OG
reducing	I-OG
bacteria	I-OG
(	O
APS	B-GP
reductase	I-GP
subunit	I-GP
A	I-GP
gene	I-GP
)	O

F	O
5	O
’-	O
TGGCAGATMATGATYMACGG	O
-	O
3	O
’	O

396	O

54	O
.	O

This	O
study	O

R	O
5	O
’-	O
GGCCGTAACCGTCCTTGAA	O
-	O
3	O
’	O


54	O
.	O
0	O


Primers	O
for	O
detection	O
and	O
quantification	O
of	O
nim	B-GP
gene	O

Primers	O
were	O
designed	O
from	O
nim	B-GP
gene	O
after	O
Stephanie	O
Trinh	O
et	O
al	O
.	O
[	O
14	O
].	O

Primer	O
sequences	O
were	O
as	O
follows	O
;	O
NIM	B-GP
-	O
F	O
(	O
5	O
’-	O
ATGTTCAGAGAAATGCGGCGTAAGCG	O
-	O
3	O
’)	O
and	O
NIM	B-GP
-	O
R	O
(	O
5	O
’-	O
GCTTCCTTGCCTGTCAT	O
GTGCTC	O
-	O
3	O
’).	O

Primers	O
Nim	B-GP
-	O
F	O
and	O
Nim	B-GP
-	O
R	O
designed	O
by	O
us	O
amplify	O
all	O
the	O
members	O
of	O
nim	B-GP
gene	O
family	O
viz	O
.	O
nimA	B-GP
,	O
nimB	B-GP
,	O
nimC	B-GP
,	O
nimD	B-GP
and	O
nimE	B-GP
.	O

Primers	O
were	O
commercially	O
synthesized	O
from	O
Sigma	O
-	O
Aldrich	O
,	O
USA	O
.	O

Primers	O
NIM	B-GP
-	O
F	O
&	O
R	O
did	O
not	O
amplify	O
genomic	O
DNA	O
derived	O
from	O
axenic	O
culture	O
of	O
E	B-OG
.	I-OG
histolytica	I-OG
HM1	I-OG
-	I-OG
IMSS	I-OG
[	O
1	O
]	O
and	O
blast	O
result	O
of	O
the	O
selected	O
primers	O
did	O
not	O
show	O
any	O
homology	O
with	O
E	B-OG
.	I-OG
histolytica	I-OG
genome	O
.	O

NIM	B-GP
-	O
F	O
&	O
R	O
primers	O
amplified	O
458	O
bp	O
fragment	O
of	O
nim	B-GP
gene	O
from	O
stool	O
sample	O
DNA	O
.	O

This	O
amplified	O
fragment	O
of	O
458	O
bp	O
was	O
cloned	O
in	O
pGEMT	O
-	O
easy	O
vector	O
and	O
sequenced	O
to	O
ensure	O
the	O
amplification	O
of	O
correct	O
gene	O
.	O

The	O
clone	O
was	O
subsequently	O
used	O
as	O
a	O
standard	O
for	O
quantification	O
of	O
nim	B-GP
gene	O
by	O
Real	O
Time	O
-	O
PCR	O
.	O

PCR	O
-	O
RFLP	O
of	O
nim	B-GP
gene	O

Primers	O
NIM	B-GP
-	O
F	O
and	O
NIM	B-GP
-	O
R	O
were	O
used	O
to	O
amplify	O
all	O
the	O
members	O
of	O
nim	B-GP
gene	O
family	O
from	O
stool	O
sample	O
DNA	O
.	O

Members	O
of	O
nim	B-GP
gene	O
family	O
were	O
differentiated	O
by	O
digesting	O
the	O
PCR	O
product	O
with	O
restriction	B-GP
enzymes	I-GP
HpaII	B-GP
and	O
TaqI	B-GP
.	O

HpaII	B-GP
digests	O
nimA	B-GP
,	O
nimC	B-GP
,	O
nimD	B-GP
at	O
different	O
loci	O
but	O
not	O
nimB	B-GP
and	O
nimE	B-GP
where	O
as	O
TaqI	B-GP
digests	O
nimA	B-GP
,	O
nimB	B-GP
,	O
nimE	B-GP
at	O
different	O
loci	O
but	O
not	O
nimC	B-GP
and	O
nimD	B-GP
[	O
19	O
].	O

Reference	O
strains	O

Genus	O
specific	O
primers	O
were	O
used	O
to	O
amplify	O
respected	O
genera	O
from	O
DNA	O
of	O
stool	O
sample	O
of	O
healthy	O
individual	O
.	O

The	O
amplified	O
product	O
was	O
cloned	O
and	O
sequenced	O
and	O
sequences	O
were	O
deposited	O
in	O
EMBL	O
database	O
to	O
obtain	O
the	O
accession	O
numbers	O
(	O
Table	O
2	O
).	O
These	O
16S	O
rRNA	O
gene	O
fragment	O
containing	O
plasmids	O
were	O
used	O
as	O
reference	O
strains	O
.	O

Accession	O
number	O
of	O
reference	O
strain	O
used	O
in	O
the	O
study	O

Bacteria	B-OG

Source	O

Accession	O
no	O
.	O

Bacteroides	B-OG

Stool	O
of	O
healthy	O
individual	O

AM117604	O

Methanobrevibacter	B-OG

Stool	O
of	O
healthy	O
individual	O

FN813615	O

Eubacterium	B-OG

Stool	O
of	O
healthy	O
individual	O

FN813614	O

Lactobacillus	B-OG

Stool	O
of	O
healthy	O
individual	O

AM042701	O

Bifidobacterium	B-OG

Stool	O
of	O
healthy	O
individual	O

AM042698	O

Clostridium	B-OG

Stool	O
of	O
healthy	O
individual	O

AM042697	O

Campylobacter	B-OG

Stool	O
of	O
healthy	O
individual	O

AM042699	O

Ruminococcus	B-OG

Stool	O
of	O
healthy	O
individual	O

FN823053	O

Sulfate	B-OG
-	I-OG
reducing	I-OG
bacteria	I-OG

Stool	O
of	O
healthy	O
individual	O

FN995351	O

Real	O
time	O
PCR	O
analysis	O
of	O
bacterial	O
population	O

Quantification	O
was	O
done	O
using	O
ABI	O
-	O
7500	O
machine	O
and	O
power	O
syber	O
green	O
PCR	O
master	O
mix	O
kit	O
from	O
Applied	O
Biosystems	O
,	O
USA	O
.	O

Standard	O
curve	O
was	O
the	O
method	O
of	O
choice	O
for	O
absolute	O
quantification	O
of	O
bacteria	B-OG
.	O

Standard	O
curve	O
was	O
made	O
using	O
serial	O
dilutions	O
of	O
plasmid	O
(	O
containing	O
16S	O
rRNA	O
gene	O
fragment	O
)	O
of	O
known	O
concentrations	O
on	O
tenfold	O
basis	O
.	O

With	O
the	O
molecular	O
weight	O
of	O
the	O
plasmid	O
and	O
insert	O
known	O
,	O
it	O
is	O
possible	O
to	O
calculate	O
the	O
copy	O
number	O
as	O
follows	O
:	O

Step	O
1	O
:	O
Determining	O
molecular	O
weight	O
(	O
mw	O
)	O

Weight	O
in	O
Daltons	O
(	O
g	O
/	O
mol	O
)	O
=	O
(	O
bp	O
size	O
of	O
double	O
stranded	O
product	O
)(	O
330	O
Da	O
x	O
2nt	O
/	O
bp	O
)	O

Step	O
2	O
:	O
Molecular	O
weight	O
to	O
copy	O
number	O

X	O
g	O
/	O
mol	O
/	O
Avogadro	O
’	O
s	O
number	O
(	O
6	O
.	O
023	O
×	O
1023	O
molecules	O
/	O
mole	O
)	O
=	O
X	O
g	O
/	O
molecule	O

Where	O
X	O
=	O
the	O
weight	O
of	O
one	O
molecule	O
or	O
copy	O

Where	O
bp	O
=	O
base	O
pairs	O
,	O
nt	O
=	O
nucleotides	O
[	O
20	O
]	O

Real	O
time	O
PCR	O
runs	O
were	O
performed	O
in	O
96	O
well	O
optical	O
plates	O
(	O
each	O
containing	O
1x	O
PCR	O
master	O
mix	O
,	O
4	O
pm	O
/	O
μl	O
forward	O
and	O
reverse	O
primer	O
(	O
optimized	O
concentration	O
)	O
and	O
1μl	O
plasmid	O
DNA	O
of	O
tenfold	O
dilutions	O
or	O
1μl	O
DNA	O
from	O
samples	O
in	O
20μl	O
reaction	O
)	O
for	O
40	O
cycles	O
using	O
an	O
ABI	O
7500	O
sequence	O
detector	O
(	O
Applied	O
biosystems	O
).	O

Default	O
7500	O
cycle	O
conditions	O
were	O
used	O
with	O
only	O
change	O
in	O
the	O
annealing	O
temperature	O
.	O

A	O
standard	O
curve	O
was	O
drawn	O
by	O
plotting	O
the	O
natural	O
log	O
of	O
the	O
threshold	O
cycle	O
(	O
Ct	O
)	O
against	O
the	O
natural	O
log	O
of	O
the	O
number	O
of	O
molecules	O
.	O

Melting	O
curves	O
were	O
obtained	O
from	O
55	O
°	O
C	O
to	O
90	O
°	O
C	O
,	O
with	O
fluorescence	O
measurements	O
taken	O
at	O
every	O
1	O
°	O
C	O
increase	O
in	O
temperature	O
.	O

All	O
reactions	O
were	O
carried	O
out	O
in	O
triplicate	O
along	O
with	O
a	O
non	O
-	O
template	O
control	O
.	O

Ct	O
values	O
were	O
calculated	O
under	O
default	O
settings	O
for	O
the	O
absolute	O
quantification	O
using	O
the	O
software	O
provided	O
with	O
the	O
instrument	O
.	O

The	O
equation	O
drawn	O
from	O
the	O
graph	O
was	O
used	O
to	O
calculate	O
the	O
precise	O
number	O
of	O
target	O
molecule	O
(	O
plasmid	O
copy	O
no	O
.	O
or	O
number	O
of	O
bacteria	B-OG
)	O
tested	O
in	O
same	O
reaction	O
plate	O
as	O
standard	O
as	O
well	O
as	O
in	O
sample	O
.	O

Statistical	O
analysis	O

Graph	O
of	O
respective	O
bacterial	O
population	O
is	O
plotted	O
as	O
mean	O
value	O
with	O
standard	O
error	O
.	O

Each	O
sample	O
was	O
analyzed	O
in	O
triplicate	O
for	O
calculation	O
of	O
significant	O
differences	O
in	O
bacterial	O
population	O
by	O
the	O
Man	O
-	O
Whitney	O
test	O
.	O

P	O
values	O
of	O
0	O
.	O
05	O
or	O
below	O
considered	O
as	O
significant	O
.	O

Paired	O
samples	O
collected	O
from	O
healthy	O
volunteers	O
before	O
and	O
after	O
satronidazole	O
treatment	O
were	O
analyzed	O
by	O
Wilcoxon	O
matched	O
-	O
pairs	O
signed	O
rank	O
test	O
(	O
two	O
tailed	O
).	O

Analysis	O
was	O
done	O
using	O
GraphPad	O
Prism	O
-	O
5	O
software	O
.	O

Results	O

Screening	O
of	O
E	B-OG
.	I-OG
histolytica	I-OG
positive	O
samples	O

DNA	O
from	O
concentrated	O
cyst	O
was	O
subjected	O
to	O
Dot	O
-	O
blot	O
hybridization	O
.	O

Dot	O
blot	O
analysis	O
of	O
550	O
samples	O
yielded	O
39	O
samples	O
(	O
7	O
%)	O
that	O
were	O
positive	O
for	O
Entamoeba	B-OG
(	O
Figure	O
1B	O
).	O

The	O
DNA	O
from	O
Entamoeba	B-OG
positive	O
samples	O
were	O
subjected	O
to	O
PCR	O
using	O
species	O
specific	O
primers	O
of	O
E	B-OG
.	I-OG
histolytica	I-OG
and	O
E	B-OG
.	I-OG
dispar	I-OG
(	O
Figure	O
2C	O
&	O
D	O
).	O
Out	O
of	O
39	O
samples	O
,	O
17	O
samples	O
(	O
43	O
%)	O
were	O
positive	O
for	O
E	B-OG
.	I-OG
histolytica	I-OG
.	O

None	O
of	O
the	O
samples	O
in	O
our	O
study	O
population	O
were	O
found	O
positive	O
for	O
both	O
the	O
species	O
of	O
the	O
parasite	O
.	O

Quantification	O
of	O
predominant	O
flora	O

High	O
quality	O
DNA	O
isolated	O
from	O
E	B-OG
.	I-OG
histolytica	I-OG
positive	O
stool	O
sample	O
was	O
subjected	O
to	O
Real	O
Time	O
analysis	O
to	O
assess	O
the	O
predominant	O
gut	B-OG
flora	I-OG
that	O
included	O
Bacteroides	B-OG
,	O
Bifidobacterium	B-OG
,	O
Eubacterium	B-OG
,	O
Clostridium	B-OG
leptum	I-OG
subgroup	O
,	O
Clostridium	B-OG
coccoides	I-OG
subgroup	O
,	O
Lactobacillus	B-OG
and	O
Ruminococcus	B-OG
.	O
Two	O
subdominant	O
genera	O
Methanobrevibacter	B-OG
smithii	I-OG
and	O
Sulphur	B-OG
reducing	I-OG
bacteria	I-OG
(	O
SRB	B-OG
)	O
were	O
also	O
quantified	O
.	O

Validation	O
of	O
primers	O
designed	O
by	O
us	O
for	O
the	O
above	O
genera	O
have	O
already	O
been	O
reported	O
[	O
21	O
].	O

In	O
addition	O
to	O
the	O
above	O
primers	O
,	O
here	O
we	O
report	O
a	O
Real	O
time	O
analysis	O
of	O
nim	B-GP
gene	O
copy	O
number	O
for	O
which	O
a	O
standard	O
curve	O
and	O
amplification	O
curve	O
have	O
been	O
drawn	O
that	O
shows	O
specific	O
and	O
efficient	O
quantification	O
with	O
slope	O
=	O
−	O
3	O
.	O
6	O
and	O
R2	O
=	O
0	O
.	O
998	O
(	O
Figure	O
3A	O
&	O
B	O
).	O

Real	O
-	O
time	O
analysis	O
for	O
quantification	O
of	O
different	O
bacterial	O
genera	O
in	O
Healthy	O
vs	O
E	B-OG
.	I-OG
histolytica	I-OG
positive	O
(	O
Eh	O
+	O
ve	O
)	O
samples	O
.	O
(	O
A	O
)	O
Bacteroides	B-OG
(	O
B	O
)	O
Clostridium	B-OG
coccoides	I-OG
subgroup	O
(	O
C	O
)	O
Clostridium	B-OG
leptum	I-OG
subgroup	O
(	O
D	O
)	O
Lactobacillus	B-OG
(	O
E	O
)	O
Campylobacter	B-OG
(	O
F	O
)	O
Eubacterium	B-OG
.	O
P	O
value	O
=	O
.	O
05	O
or	O
below	O
was	O
considered	O
significant	O
.	O

CI	O
stands	O
for	O
confidence	O
interval	O
.	O

Our	O
analysis	O
reveals	O
that	O
during	O
healthy	O
conditions	O
,	O
the	O
members	O
of	O
Bacteroides	B-OG
were	O
the	O
most	O
abundant	O
in	O
number	O
among	O
the	O
predominant	O
targeted	O
genera	O
.	O

However	O
,	O
a	O
significant	O
decrease	O
was	O
observed	O
in	O
population	O
of	O
Bacteroides	B-OG
(	O
p	O
=	O
.	O
001	O
)	O
in	O
E	B-OG
.	I-OG
histolytica	I-OG
positive	O
samples	O
when	O
compared	O
to	O
that	O
of	O
Healthy	O
control	O
samples	O
(	O
Figure	O
4A	O
).	O

Simultaneously	O
,	O
we	O
also	O
observed	O
a	O
significant	O
decrease	O
in	O
the	O
population	O
of	O
Closrtridium	B-OG
coccoides	I-OG
subgroup	O
(	O
p	O
=	O
0	O
.	O
002	O
),	O
Clostridium	B-OG
leptum	I-OG
subgroup	O
(	O
p	O
=	O
0	O
.	O
0001	O
),	O
Lactobacillus	B-OG
(	O
p	O
=	O
0	O
.	O
037	O
),	O
Campylobacter	B-OG
(	O
p	O
=	O
0	O
.	O
0014	O
)	O
and	O
Eubacterium	B-OG
(	O
p	O
=	O
0	O
.	O
038	O
)	O
in	O
E	B-OG
.	I-OG
histolytica	I-OG
positive	O
samples	O
in	O
comparison	O
to	O
control	O
(	O
Figure	O
4B	O
,	O
C	O
,	O
D	O
,	O
E	O
and	O
F	O
respectively	O
).	O

Surprisingly	O
,	O
we	O
observed	O
a	O
significant	O
rise	O
in	O
the	O
population	O
of	O
Bifidobacterium	B-OG
(	O
p	O
=	O
0	O
.	O
009	O
)	O
in	O
amebic	O
samples	O
when	O
compared	O
with	O
healthy	O
control	O
samples	O
(	O
Figure	O
5B	O
).	O

No	O
significant	O
changes	O
were	O
observed	O
in	O
population	O
of	O
Rumminococcus	B-OG
(	O
p	O
=	O
0	O
.	O
33	O
)	O
(	O
Figure	O
5A	O
).	O

Though	O
we	O
did	O
not	O
observe	O
any	O
significant	O
change	O
in	O
the	O
population	O
of	O
Methanobrevibacter	B-OG
(	O
p	O
=	O
0	O
.	O
96	O
)	O
and	O
Sulphur	B-OG
reducing	I-OG
bacteria	I-OG
(	O
p	O
=	O
0	O
.	O
88	O
)	O
in	O
amoebic	O
samples	O
but	O
the	O
prevalence	O
rate	O
was	O
reduced	O
(	O
Additional	O
file	O
1	O
:	O
Figure	O
S1A	O
&	O
B	O
).	O

Real	O
-	O
time	O
analysis	O
of	O
population	O
of	O
(	O
A	O
)	O
Rumminococcus	B-OG
in	O
Healthy	O
vs	O
E	B-OG
.	I-OG
histolytica	I-OG
positive	O
(	O
Eh	O
+	O
ve	O
)	O
samples	O
(	O
B	O
)	O
Bifidobacterium	B-OG
in	O
Healthy	O
vs	O
E	B-OG
.	I-OG
histolytica	I-OG
positive	O
(	O
Eh	O
+	O
ve	O
)	O
samples	O
.	O
P	O
value	O
=	O
.	O
05	O
or	O
below	O
was	O
considered	O
significant	O
.	O

CI	O
stands	O
for	O
confidence	O
interval	O
.	O

Detection	O
and	O
identification	O
of	O
nim	B-GP
gene	O
in	O
stool	O
samples	O
.	O
(	O
A	O
)	O
Detection	O
of	O
nim	B-GP
gene	O
using	O
nim	B-GP
gene	O
specific	O
primers	O
.	O

Lane	O
1	O
=	O
Marker	O
100	O
bp	O
,	O
Lane	O
2	O
=	O
clone	O
of	O
nim	B-GP
gene	O
as	O
positive	O
control	O
,	O
Lane	O
3	O
–	O
5	O
=	O
DNA	O
from	O
stool	O
samples	O
from	O
healthy	O
volunteer	O
,	O
Lane	O
6	O
–	O
8	O
=	O
DNA	O
from	O
stool	O
samples	O
from	O
E	B-OG
.	I-OG
histolytica	I-OG
positive	O
patients	O
and	O
Lane	O
9	O
=	O
No	O
template	O
control	O
PCR	O
(	O
B	O
)	O
Restriction	O
map	O
of	O
TaqI	B-GP
restriction	O
sites	O
in	O
458	O
bp	O
nimE	B-GP
gene	O
fragment	O
.	O

(	O
C	O
)	O
HpaII	B-GP
does	O
not	O
digest	O
nimE	B-GP
,	O
where	O
as	O
digestion	O
of	O
nimE	B-GP
by	O
TaqI	B-GP
generates	O
four	O
fragment	O
of	O
274	O
bp	O
,	O
155	O
bp	O
,	O
6	O
bp	O
and	O
25	O
bp	O
.	O

Lane	O
1	O
=	O
Marker	O
100	O
bp	O
,	O
Lane	O
H1	O
,	O
H2	O
,	O
E1	O
and	O
E2	O
show	O
RFLP	O
profile	O
of	O
PCR	O
product	O
digested	O
with	O
HpaII	B-GP
;	O
Lane	O
H3	O
,	O
H4	O
,	O
E3	O
and	O
E4	O
show	O
RFLP	O
profile	O
of	O
PCR	O
product	O
digested	O
with	O
TaqI	B-GP
.	O

H1	O
-	O
H4	O
,	O
DNA	O
from	O
stool	O
samples	O
of	O
Healthy	O
volunteers	O
and	O
E1	O
-	O
E4	O
are	O
DNA	O
from	O
stool	O
samples	O
of	O
E	B-OG
.	I-OG
histolytica	I-OG
positive	O
patients	O
.	O

Copy	O
no	O
.	O
of	O
nim	B-GP
gene	O

We	O
found	O
the	O
presence	O
of	O
nim	B-GP
genes	O
in	O
72	O
.	O
7	O
%	O
of	O
control	O
stool	O
samples	O
(	O
n	O
=	O
22	O
)	O
and	O
in	O
41	O
%	O
of	O
Entamoeba	B-OG
histolytica	I-OG
infected	O
patients	O
(	O
n	O
=	O
17	O
)	O
by	O
PCR	O
(	O
Figure	O
6A	O
).	O

Further	O
the	O
amplified	O
product	O
was	O
cloned	O
and	O
sequenced	O
.	O

BLAST	O
analysis	O
revealed	O
99	O
%	O
sequence	O
homology	O
with	O
nimE	B-GP
gene	O
(	O
Accession	O
no	O
.	O
AM117602	O
.	O
1	O
),	O
a	O
member	O
of	O
nim	B-GP
gene	O
family	O
[	O
22	O
].	O

Subsequently	O
,	O
the	O
PCR	O
products	O
from	O
all	O
the	O
samples	O
of	O
healthy	O
and	O
amebic	O
individuals	O
were	O
subjected	O
to	O
RFLP	O
analysis	O
using	O
HpaII	B-GP
and	O
TaqI	B-GP
restriction	B-GP
enzymes	I-GP
.	O

PCR	O
-	O
RFLP	O
pattern	O
confirmed	O
the	O
presence	O
of	O
only	O
nimE	B-GP
gene	O
in	O
all	O
the	O
samples	O
analyzed	O
(	O
Figure	O
6B	O
&	O
C	O
).	O

Real	O
time	O
analysis	O
of	O
nim	B-GP
gene	O
in	O
the	O
stool	O
samples	O
exhibited	O
sample	O
to	O
sample	O
variation	O
(	O
4	O
×	O
102	O
to	O
4	O
×	O
105	O
copies	O
)	O
in	O
the	O
both	O
category	O
of	O
samples	O
.	O

We	O
observed	O
a	O
significant	O
increase	O
in	O
copy	O
no	O
.	O
of	O
nim	B-GP
gene	O
in	O
E	B-OG
.	I-OG
histolytica	I-OG
positive	O
samples	O
vs	O
samples	O
from	O
healthy	O
persons	O
(	O
p	O
=	O
0	O
.	O
025	O
)	O
(	O
Figure	O
3C	O
).	O

Detemination	O
of	O
copy	O
number	O
of	O
nimE	B-GP
gene	O
by	O
Real	O
-	O
time	O
PCR	O
.	O
(	O
A	O
)	O
Standard	O
curve	O
,	O
slope	O
=	O
−	O
3	O
.	O
6	O
and	O
R2	O
=	O
0	O
.	O
998	O
showing	O
good	O
efficiency	O
.	O

(	O
B	O
)	O
Dissociation	O
curve	O
showing	O
specific	O
amplification	O
of	O
target	O
(	O
nimE	B-GP
gene	O
)	O
and	O
NTC	O
=	O
No	O
template	O
control	O
.	O

(	O
C	O
)	O
Absolute	O
quantification	O
of	O
copy	O
no	O
.	O
of	O
nimE	B-GP
gene	O
in	O
Healthy	O
vs	O
E	B-OG
.	I-OG
histolytica	I-OG
positive	O
samples	O
.	O

(	O
D	O
)	O
Absolute	O
quantification	O
of	O
copy	O
no	O
.	O
of	O
nimE	B-GP
gene	O
in	O
stool	O
sample	O
DNA	O
of	O
Healthy	O
volunteers	O
before	O
and	O
after	O
satronidazole	O
treatment	O
.	O

P	O
value	O
=	O
.	O
05	O
or	O
below	O
was	O
considered	O
significant	O
.	O

CI	O
stands	O
for	O
confidence	O
interval	O
.	O

To	O
see	O
the	O
effect	O
of	O
antiamoebic	O
drug	O
Satronidazole	O
(	O
Alchem	O
pharmaceuticals	O
)	O
on	O
nim	B-GP
gene	O
copy	O
number	O
,	O
healthy	O
volunteers	O
(	O
n	O
=	O
5	O
)	O
were	O
advised	O
to	O
take	O
the	O
drug	O
(	O
300	O
mg	O
tablets	O
)	O
twice	O
daily	O
after	O
meals	O
for	O
4	O
days	O
and	O
copy	O
of	O
nim	B-GP
gene	O
was	O
quantified	O
before	O
and	O
after	O
the	O
treatment	O
using	O
the	O
primers	O
described	O
here	O
.	O

Wilcoxon	O
matched	O
-	O
pairs	O
signed	O
rank	O
test	O
(	O
two	O
tailed	O
)	O
analysis	O
of	O
copy	O
no	O
.	O
of	O
nim	B-GP
gene	O
shows	O
no	O
significant	O
change	O
(	O
p	O
=	O
0	O
.	O
125	O
)	O
in	O
stool	O
samples	O
collected	O
before	O
and	O
after	O
treatment	O
(	O
Figure	O
3D	O
).	O

Discussion	O

Infection	B-DS
by	O
E	B-OG
.	I-OG
histolytica	I-OG
is	O
normally	O
initiated	O
by	O
the	O
ingestion	O
of	O
fecally	O
contaminated	O
water	O
or	O
food	O
containing	O
E	B-OG
.	I-OG
histolytica	I-OG
cysts	O
.	O

Phagocytosis	O
of	O
colonic	O
bacteria	B-OG
has	O
been	O
considered	O
as	O
a	O
possible	O
stimulus	O
to	O
induce	O
the	O
invasive	O
behavior	O
by	O
the	O
parasite	O
[	O
23	O
].	O

Adult	O
gut	O
microbiota	B-OG
are	O
quite	O
stable	O
in	O
individuals	O
and	O
can	O
even	O
be	O
restored	O
after	O
perturbation	O
[	O
24	O
,	O
25	O
].	O

Our	O
earlier	O
results	O
have	O
shown	O
significant	O
changes	O
in	O
expression	O
of	O
EhCaBP	B-GP
and	O
LPG	B-GP
only	O
after	O
the	O
axenic	O
E	B-OG
.	I-OG
histolytica	I-OG
had	O
been	O
adapted	O
to	O
grow	O
with	O
bacterial	O
flora	O
for	O
a	O
number	O
of	O
generatiom	O
,	O
and	O
not	O
in	O
short	O
term	O
culture	O
[	O
26	O
].	O

In	O
the	O
present	O
study	O
we	O
tried	O
to	O
evaluate	O
perturbations	O
in	O
commensal	O
gut	B-OG
flora	I-OG
caused	O
as	O
result	O
of	O
E	B-DS
.	I-DS
histolytica	I-DS
infection	I-DS
using	O
Real	O
Time	O
PCR	O
.	O

qPCR	O
methodology	O
is	O
less	O
expensive	O
,	O
more	O
quantitative	O
and	O
is	O
more	O
efficient	O
in	O
terms	O
of	O
time	O
and	O
operation	O
[	O
27	O
].	O

The	O
absolute	O
proportions	O
of	O
eight	O
predominant	O
commensal	O
and	O
two	O
subdominant	O
genera	O
were	O
quantified	O
successfully	O
in	O
our	O
samples	O
.	O

Bacteroides	B-OG
species	O
are	O
a	O
pleomorphic	O
group	O
of	O
non	O
-	O
spore	O
forming	O
gram	B-OG
-	I-OG
negative	I-OG
anaerobic	I-OG
bacteria	I-OG
.	O

Bacteroides	B-OG
are	O
the	O
most	O
dominant	O
part	O
of	O
the	O
normal	O
indigenous	O
flora	O
in	O
the	O
human	B-OG
gut	O
.	O
Bacteroides	B-OG
are	O
mostly	O
represented	O
by	O
Bacteroides	B-OG
ovatus	I-OG
,	O
Bacteroides	B-OG
uniformis	I-OG
Bacteroides	B-OG
vulgatus	I-OG
,	O
Bacteroides	B-OG
thetaiotaomicron	I-OG
,	O
Bacteroides	B-OG
distasonis	I-OG
,	O
and	O
less	O
frequently	O
by	O
Bacteroides	B-OG
eggerthii	I-OG
and	O
Bacteroides	B-OG
fragilis	I-OG
.	O
These	O
bacteria	B-OG
are	O
significant	O
contributors	O
to	O
the	O
carbohydrate	O
metabolism	O
,	O
nutrition	O
and	O
health	O
of	O
humans	B-OG
and	O
animals	B-OG
.	O

In	O
1999	O
Hooper	O
et	O
al	O
.	O
demonstrated	O
that	O
B	B-OG
.	I-OG
thetaiotaomicron	I-OG
can	O
modify	O
intestinal	O
fucosylation	O
in	O
a	O
complex	O
interaction	O
mediated	O
by	O
fucose	B-GP
repressor	I-GP
gene	I-GP
and	O
a	O
signaling	O
system	O
[	O
28	O
].	O

The	O
significant	O
decrease	O
in	O
population	O
of	O
Bacteroides	B-OG
during	O
disease	O
condition	O
dampens	O
the	O
beneficial	O
effects	O
of	O
this	O
genera	O
to	O
host	O
.	O

In	O
the	O
human	B-OG
intestinal	O
tract	O
,	O
Eubacterium	B-OG
is	O
the	O
second	O
most	O
common	O
genus	O
after	O
the	O
genus	O
Bacteroides	B-OG
.	O
The	O
genus	O
Eubacterium	B-OG
comprises	O
a	O
nutritionally	O
diverse	O
group	O
of	O
organisms	O
.	O

The	O
members	O
of	O
genus	O
Eubacterium	B-OG
are	O
known	O
to	O
produce	O
butyrate	O
[	O
29	O
],	O
degrade	O
flavonoids	O
(	O
from	O
vegetables	O
,	O
fruits	O
,	O
nuts	O
,	O
and	O
tea	O
)	O
[	O
30	O
]	O
and	O
are	O
implicated	O
in	O
steroid	O
and	O
bile	O
transformation	O
in	O
intestine	O
[	O
31	O
].	O

The	O
decrease	O
in	O
population	O
of	O
Eubacterium	B-OG
sp	O
.	O
observed	O
in	O
our	O
study	O
may	O
reduce	O
the	O
butyrate	O
production	O
and	O
may	O
also	O
affect	O
the	O
capacity	O
of	O
the	O
host	O
in	O
proper	O
digestion	O
of	O
the	O
above	O
ingredients	O
of	O
food	O
.	O

Bifidobacterium	B-OG
species	O
are	O
common	O
inhabitants	O
of	O
the	O
gastrointestinal	O
tract	O
,	O
and	O
they	O
have	O
received	O
special	O
attention	O
because	O
of	O
their	O
health	O
-	O
promoting	O
effects	O
in	O
humans	B-OG
.	O

Members	O
of	O
Bifidobacteria	B-OG
produce	O
enough	O
acetate	O
(	O
SCFA	O
)	O
in	O
proximal	O
and	O
distal	O
colon	O
by	O
fermentation	O
of	O
glucose	O
and	O
fructose	O
[	O
32	O
].	O

Members	O
of	O
both	O
Bifidobacteria	B-OG
and	O
Ruminococcus	B-OG
-	O
Ruminococcus	B-OG
torques	I-OG
and	O
Bifidobacterium	B-OG
bifidum	I-OG
are	O
thought	O
to	O
ferment	O
mucin	B-GP
and	O
compete	O
to	O
colonise	O
this	O
substrate	O
for	O
their	O
energy	O
source	O
[	O
33	O
].	O

Our	O
result	O
shows	O
a	O
significant	O
increase	O
in	O
population	O
of	O
Bifidobacterium	B-OG
but	O
no	O
change	O
in	O
population	O
of	O
Rumminococcous	B-OG
despite	O
decrease	O
in	O
population	O
of	O
several	O
other	O
targeted	O
genera	O
.	O

It	O
is	O
quite	O
well	O
known	O
that	O
mucus	O
secretion	O
is	O
increased	O
in	O
E	B-DS
.	I-DS
histolytica	I-DS
infection	I-DS
especially	O
during	O
dysentery	B-DS
which	O
is	O
probably	O
result	O
of	O
a	O
mechanism	O
exerted	O
by	O
intestinal	O
epithelial	O
cells	O
to	O
counter	O
the	O
adherence	O
of	O
E	B-OG
.	I-OG
histolytica	I-OG
trophozoites	O
to	O
intestinal	O
epithelial	O
surface	O
.	O

The	O
protozoan	O
parasite	O
Entamoeba	B-OG
histolytica	I-OG
cleaves	O
Mucin	B-GP
2	I-GP
(	O
MUC2	B-GP
)	O
in	O
the	O
non	O
-	O
glycosylated	O
oligomerization	O
domains	O
by	O
cysteine	B-GP
protease	I-GP
,	O
thus	O
breaking	O
down	O
the	O
macromolecular	O
structure	O
and	O
reducing	O
mucus	O
viscosity	O
[	O
34	O
].	O

Perhaps	O
under	O
this	O
condition	O
,	O
a	O
cross	O
-	O
talk	O
between	O
the	O
mucosal	O
layer	O
,	O
bacteria	B-OG
and	O
the	O
parasite	O
initiates	O
.	O

As	O
a	O
result	O
,	O
the	O
intestinal	O
epithelial	O
cells	O
tend	O
to	O
produce	O
more	O
of	O
mucin	B-GP
for	O
protection	O
that	O
promotes	O
colonization	O
of	O
Bifidobacteria	B-OG
in	O
one	O
hand	O
and	O
on	O
the	O
other	O
hand	O
the	O
parasite	O
competes	O
to	O
more	O
release	O
of	O
mucin	B-GP
for	O
its	O
adhesion	O
to	O
epithelial	O
layer	O
.	O
Bifidobacteria	B-OG
longum	I-OG
are	O
known	O
to	O
protect	O
the	O
gut	O
from	O
enteropathogenic	O
infection	B-DS
through	O
production	O
of	O
acetate	O
[	O
32	O
]	O
and	O
acetate	O
is	O
major	O
energy	O
source	O
for	O
colonocytes	O
but	O
a	O
fine	O
balance	O
in	O
population	O
of	O
different	O
bacterial	O
genera	O
of	O
gut	O
is	O
needed	O
for	O
healthy	O
colon	O
.	O

The	O
C	B-OG
.	I-OG
leptum	I-OG
subgroup	O
and	O
C	B-OG
.	I-OG
coccoides	I-OG
subgroup	O
are	O
one	O
of	O
the	O
most	O
predominant	O
populations	O
of	O
human	B-OG
fecal	O
microflora	O
which	O
contains	O
a	O
large	O
number	O
of	O
butyrate	O
-	O
producing	O
bacteria	B-OG
[	O
35	O
,	O
36	O
].	O

Butyrate	O
is	O
a	O
SCFA	O
(	O
Short	O
chain	O
fatty	O
acids	O
)	O
having	O
a	O
strong	O
effect	O
on	O
the	O
cell	O
cycle	O
and	O
acts	O
as	O
anti	O
-	O
inflammatory	O
molecule	O
in	O
the	O
gut	O
.	O

Effects	O
on	O
mucosal	O
defense	O
include	O
improved	O
tight	O
junction	O
assembly	O
,	O
antimicrobial	O
secretion	O
and	O
mucin	B-GP
expression	O
[	O
37	O
].	O

The	O
decrease	O
in	O
population	O
of	O
members	O
of	O
C	B-OG
.	I-OG
leptum	I-OG
subgroup	O
and	O
C	B-OG
.	I-OG
coccoides	I-OG
subgroup	O
observed	O
here	O
leads	O
to	O
decrease	O
in	O
the	O
production	O
of	O
SCFA	O
and	O
hence	O
renders	O
the	O
host	O
more	O
susceptible	O
for	O
future	O
infections	B-DS
.	O

The	O
genus	O
Lactobacillus	B-OG
comprises	O
a	O
large	O
heterogenous	O
group	O
of	O
low	O
G	O
+	O
C	O
gram	O
positive	O
,	O
non	O
sporulating	O
,	O
anaerobic	O
bacteria	B-OG
belonging	O
to	O
phylum	O
Firmicutes	B-OG
.	O
Lactobacilli	B-OG
are	O
known	O
to	O
fortify	O
epithelial	O
barrier	O
by	O
various	O
mechanism	O
such	O
as	O
induction	O
of	O
mucin	B-GP
secretion	O
,	O
enhancement	O
of	O
tight	O
-	O
junction	O
functioning	O
,	O
upregulation	O
of	O
cytoprotective	O
heat	B-GP
shock	I-GP
proteins	I-GP
and	O
prevention	O
of	O
apoptosis	O
of	O
epithelial	O
cells	O
[	O
38	O
].	O

Probiotic	O
strains	O
of	O
Lactobacillus	B-OG
are	O
known	O
to	O
prevent	O
infectious	B-DS
diarrhea	I-DS
,	O
antibiotic	B-DS
associated	I-DS
diarrhea	I-DS
and	O
diarrhea	O
in	O
children	O
who	O
are	O
unusually	O
more	O
susceptible	O
as	O
a	O
result	O
of	O
poor	O
nutrition	O
,	O
impaired	O
immune	O
status	O
or	O
frequent	O
exposure	O
to	O
pathogens	O
[	O
39	O
].	O

We	O
observed	O
significant	O
decrease	O
in	O
population	O
of	O
Lactobacillus	B-OG
in	O
gut	B-OG
flora	I-OG
of	O
E	B-OG
.	I-OG
histolytica	I-OG
positive	O
patients	O
as	O
compared	O
to	O
that	O
of	O
healthy	O
individuals	O
that	O
support	O
our	O
earlier	O
observation	O
made	O
by	O
semi	O
quantitative	O
method	O
[	O
1	O
].	O

Methanobrevibacter	B-OG
smithii	I-OG
is	O
the	O
dominant	O
archaeon	O
in	O
human	B-OG
gut	O
that	O
affects	O
the	O
specificity	O
and	O
efficiency	O
of	O
bacterial	O
digestion	O
of	O
dietary	O
polysaccharides	O
,	O
thereby	O
influencing	O
host	O
calorie	O
harvest	O
and	O
adiposity	O
[	O
40	O
].	O

It	O
has	O
been	O
suggested	O
that	O
the	O
low	O
and	O
variable	O
prevalence	O
of	O
Methanobrevibacter	B-OG
smithii	I-OG
and	O
Methanosphaera	B-OG
stadtmanae	I-OG
DNA	O
in	O
human	B-OG
stool	O
contrasts	O
with	O
the	O
paramount	O
role	O
of	O
these	O
methanogenic	B-OG
archaea	I-OG
in	O
digestion	O
processes	O
and	O
hypothesized	O
that	O
this	O
contrast	O
is	O
a	O
consequence	O
of	O
the	O
inefficiencies	O
of	O
current	O
protocols	O
for	O
archaea	B-OG
DNA	O
extraction	O
[	O
41	O
].	O

In	O
our	O
samples	O
prevalence	O
of	O
M	B-OG
.	I-OG
smithii	I-OG
in	O
healthy	O
individuals	O
stool	O
samples	O
was	O
27	O
.	O
27	O
%	O
and	O
that	O
was	O
further	O
reduced	O
to	O
11	O
.	O
7	O
%	O
in	O
E	B-OG
.	I-OG
histolytica	I-OG
positive	O
samples	O
.	O

Real	O
-	O
time	O
analysis	O
shows	O
no	O
significant	O
alteration	O
in	O
population	O
of	O
M	B-OG
.	I-OG
smithii	I-OG
.	O

Variation	O
in	O
the	O
loads	O
of	O
M	B-OG
.	I-OG
smithii	I-OG
under	O
different	O
pathophysiological	O
condition	O
such	O
as	O
during	O
amebiasis	B-DS
has	O
not	O
been	O
reported	O
so	O
far	O
.	O

Suphate	B-OG
reducing	I-OG
bacteria	I-OG
(	O
SRB	B-OG
)	O
are	O
a	O
group	O
of	O
non	O
spore	O
forming	O
,	O
gram	O
negative	O
,	O
dissimilatory	O
sulphate	O
reducing	O
,	O
anaerobic	O
bacteria	B-OG
.	O

SRB	B-OG
can	O
be	O
isolated	O
from	O
the	O
intestinal	O
tract	O
of	O
humans	B-OG
and	O
various	O
environmental	O
sources	O
.	O

Intestinal	O
SRB	B-OG
’	O
s	O
growth	O
and	O
resultant	O
hydrogen	O
sulfide	O
production	O
have	O
been	O
implicated	O
to	O
damage	O
the	O
gastrointestinal	O
tract	O
and	O
thereby	O
contribute	O
to	O
chronic	O
intestinal	B-DS
disorders	I-DS
[	O
42	O
].	O
Desulfovibrio	B-OG
fairfieldensis	I-OG
and	O
D	B-OG
.	I-OG
desulfuricans	I-OG
have	O
been	O
associated	O
with	O
incidence	O
of	O
bacteremia	B-DS
and	O
D	B-OG
.	I-OG
vulgaris	I-OG
has	O
been	O
associated	O
with	O
intra	B-DS
-	I-DS
abdominal	I-DS
infections	I-DS
[	O
43	O
].	O

The	O
prevalence	O
of	O
Sulphate	B-OG
reducing	I-OG
bacteria	I-OG
was	O
36	O
.	O
36	O
%	O
in	O
healthy	O
and	O
11	O
.	O
7	O
%	O
in	O
amoebic	O
individuals	O
stool	O
samples	O
.	O

However	O
,	O
the	O
change	O
was	O
not	O
statistically	O
significant	O
.	O

The	O
genus	O
Campylobacter	B-OG
is	O
notorious	O
for	O
causing	O
gastroenritis	B-DS
by	O
C	B-OG
.	I-OG
jejuni	I-OG
but	O
uncultured	O
Campylobacter	B-OG
species	O
e	O
.	O
g	O
.	O
Campylobacter	B-OG
hominis	I-OG
whose	O
role	O
is	O
not	O
clear	O
yet	O
,	O
do	O
exist	O
in	O
lower	O
gastrointestinal	O
tract	O
of	O
healthy	O
humans	B-OG
[	O
44	O
].	O

We	O
observed	O
significant	O
decrease	O
in	O
population	O
of	O
Campylobacter	B-OG
in	O
E	B-OG
.	I-OG
histolytica	I-OG
positive	O
individual	O
as	O
compared	O
to	O
healthy	O
individuals	O
.	O

As	O
our	O
primers	O
were	O
genus	O
specific	O
,	O
so	O
decrease	O
in	O
Campylobacter	B-OG
was	O
genera	O
specific	O
and	O
not	O
species	O
specific	O
.	O

Significant	O
increase	O
in	O
the	O
population	O
of	O
Campylobacter	B-OG
has	O
been	O
observed	O
in	O
IBD	B-DS
[	O
21	O
]	O
but	O
we	O
did	O
not	O
find	O
the	O
same	O
trend	O
in	O
amoebic	O
patients	O
.	O

Several	O
species	O
of	O
Bacteroides	B-OG
are	O
known	O
to	O
harbor	O
nim	B-GP
genes	O
e	O
.	O
g	O
.	O
B	B-OG
.	I-OG
fragilis	I-OG
,	O
B	B-OG
.	I-OG
distasonis	I-OG
,	O
B	B-OG
.	I-OG
thetaiotaomicron	I-OG
,	O
B	B-OG
.	I-OG
vulgatus	I-OG
,	O
B	B-OG
.	I-OG
ovatus	I-OG
but	O
wide	O
differences	O
in	O
MIC	O
values	O
of	O
metronidazole	O
are	O
observed	O
,	O
ranging	O
from	O
1	O
.	O
5	O
to	O
>	O
256	O
mg	O
/	O
L	O
and	O
some	O
are	O
also	O
found	O
above	O
the	O
therapeutic	O
breakpoint	O
of	O
16	O
mg	O
/	O
L	O
[	O
45	O
].	O
Though	O
the	O
population	O
of	O
Bacteroides	B-OG
is	O
decreased	O
significantly	O
in	O
E	B-OG
.	I-OG
histolytica	I-OG
positive	O
patients	O
however	O
we	O
have	O
observed	O
high	O
copy	O
no	O
.	O
of	O
nimE	B-GP
gene	O
in	O
the	O
same	O
.	O

We	O
attribute	O
this	O
increase	O
to	O
the	O
presence	O
of	O
plasmid	O
coded	O
nimE	B-GP
gene	O
as	O
has	O
been	O
observed	O
earlier	O
in	O
Veillonella	B-OG
sp	I-OG
.	O

[	O
46	O
].	O

Future	O
analyses	O
that	O
target	O
specific	O
members	O
of	O
the	O
Bacteroides	B-OG
group	O
will	O
shed	O
further	O
light	O
on	O
the	O
species	O
involved	O
in	O
the	O
expansion	O
of	O
nimE	B-GP
gene	O
.	O
In	O
2006	O
,	O
Rani	O
et	O
al	O
.	O
reported	O
presence	O
of	O
nim	B-GP
gene	O
in	O
stool	O
samples	O
of	O
amebic	O
individuals	O
but	O
not	O
in	O
healthy	O
individuals	O
[	O
1	O
]	O
but	O
our	O
result	O
show	O
high	O
prevalence	O
rate	O
of	O
nim	B-GP
gene	O
even	O
in	O
healthy	O
individuals	O
irrespective	O
of	O
the	O
disease	O
.	O

However	O
in	O
a	O
hospital	O
based	O
study	O
carried	O
out	O
in	O
Greece	O
revealed	O
low	O
level	O
of	O
prevalence	O
of	O
nim	B-GP
gene	O
in	O
isolates	O
of	O
different	O
anaerobic	O
bacterial	O
species	O
from	O
hospitalized	O
patients	O
[	O
47	O
].	O

Though	O
the	O
presence	O
of	O
nim	B-GP
gene	O
in	O
gut	O
of	O
healthy	O
north	O
Indian	O
population	O
is	O
shocking	O
but	O
this	O
may	O
be	O
explained	O
due	O
to	O
easy	O
over	O
the	O
counter	O
drug	O
availability	O
in	O
India	O
.	O

Results	O
on	O
healthy	O
individuals	O
undergoing	O
Satronidazole	O
treatment	O
indicate	O
that	O
nimE	B-GP
gene	O
copy	O
number	O
does	O
not	O
show	O
significant	O
reduction	O
.	O

It	O
can	O
therefore	O
be	O
assumed	O
that	O
nimE	B-GP
gene	O
harboring	O
Bacteroides	B-OG
probably	O
cause	O
inactivation	O
of	O
nitroimidazole	O
drug	O
and	O
thereby	O
reduce	O
the	O
bioavailability	O
of	O
drug	O
to	O
the	O
parasite	O
and	O
hence	O
may	O
help	O
in	O
sustaining	O
the	O
infection	B-DS
.	O

Conclusion	O

The	O
metabolic	O
activities	O
of	O
the	O
predominant	O
gut	B-OG
flora	I-OG
have	O
a	O
significant	O
effect	O
on	O
the	O
health	O
of	O
the	O
human	B-OG
colon	O
.	O

The	O
current	O
findings	O
of	O
depleted	O
populations	O
of	O
metabolically	O
important	O
bacteria	B-OG
like	O
Bacteroides	B-OG
,	O
C	B-OG
.	I-OG
leptum	I-OG
and	O
C	B-OG
.	I-OG
coccoides	I-OG
sub	O
groups	O
,	O
Lactobacillus	B-OG
sp	I-OG
.,	O
Eubacterium	B-OG
sp	O
.,	O
and	O
Campylobacter	B-OG
sp	I-OG
.	I-OG
add	O
to	O
our	O
knowledge	O
of	O
the	O
changes	O
in	O
the	O
GI	O
tracts	O
of	O
amebic	O
patients	O
.	O

Such	O
changes	O
in	O
bacterial	O
population	O
in	O
the	O
normal	O
microbiota	B-OG
could	O
have	O
considerable	O
consequences	O
in	O
terms	O
of	O
functional	O
potential	O
of	O
gut	B-OG
flora	I-OG
and	O
could	O
result	O
in	O
metabolic	O
conditions	O
favorable	O
for	O
the	O
establishment	O
of	O
opportunistic	O
pathogens	O
(	O
e	O
.	O
g	O
.	O
Clostridium	B-OG
difficile	I-OG
).	O

However	O
,	O
our	O
study	O
cannot	O
conclude	O
that	O
observed	O
changes	O
in	O
the	O
gut	B-OG
flora	I-OG
is	O
the	O
cause	O
or	O
effect	O
of	O
the	O
infection	B-DS
or	O
the	O
effect	O
of	O
dysenteric	O
mechanism	O
per	O
se	O
by	O
the	O
parasite	O
.	O

Our	O
findings	O
could	O
potentially	O
guide	O
implementation	O
of	O
dietary	O
/	O
probiotic	O
interventions	O
that	O
impact	O
the	O
gut	O
microbiota	B-OG
and	O
improve	O
GI	O
health	O
in	O
individuals	O
infected	O
with	O
Entamoeba	B-OG
histolytica	I-OG
.	O

Abbreviations	O

SRB	B-OG
:	O
Sulphur	B-OG
reducing	I-OG
bacteria	I-OG
;	O
RFLP	O
:	O
Restriction	O
fragment	O
length	O
polymorphism	O
;	O
MUC2	B-GP
:	O
Mucin	B-GP
2	I-GP
;	O
SCFA	O
:	O
Short	O
-	O
chain	O
.	O

Competing	O
interests	O

We	O
declare	O
that	O
no	O
competing	O
interests	O
exist	O
among	O
the	O
authors	O

Authors	O
’	O
contributions	O

JP	O
conceived	O
and	O
coordinated	O
the	O
study	O
.	O

AKV	O
carried	O
out	O
the	O
bacterial	O
quantification	O
experiments	O
.	O

AKV	O
and	O
RV	O
conducted	O
the	O
copy	O
number	O
calculation	O
experiments	O
.	O

JP	O
and	O
AKV	O
drafted	O
the	O
manuscript	O
and	O
conducted	O
the	O
statistical	O
analysis	O
.	O

VA	O
made	O
the	O
diagnosis	O
of	O
the	O
patients	O
,	O
interpretation	O
of	O
data	O
and	O
collaborated	O
in	O
collection	O
of	O
the	O
samples	O
.	O

All	O
authors	O
read	O
and	O
approved	O
the	O
final	O
manuscript	O
.	O

Supplementary	O
Material	O

Additional	O
file	O
1	O

Real	O
time	O
analysis	O
of	O
population	O
of	O
(	O
A	O
)	O
Methanobrevibacter	B-OG
in	O
Healthy	O
vs	O
E	B-OG
.	I-OG
histolytica	I-OG
positive	O
samples	O
(	O
B	O
)	O
Sulphur	B-OG
reducing	I-OG
bacteria	I-OG
in	O
Healthy	O
vs	O
E	B-OG
.	I-OG
histolytica	I-OG
positive	O
sample	O
.	O

P	O
value	O
=	O
.	O
05	O
or	O
below	O
was	O
considered	O
significant	O
.	O
Cl	O
stands	O
for	O
confidence	O
interval	O
.	O

Click	O
here	O
for	O
file	O

